Rhythm Pharmaceuticals, Inc. (RYTM) is a leading biopharmaceutical company focused on the development and commercialization of breakthrough, innovative therapies for the treatment of rare genetic disorders of obesity. The company was incorporated in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals leverages its deep understanding of the biology of these disorders and uses this knowledge to develop specific, targeted treatments designed to significantly improve the lives of patients affected by obesity and the metabolic dysfunction that often accompanies this condition.
Rhythm Pharmaceuticals is widely known for its lead product candidate setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Setmelanotide has been developed to restore the function of impaired MC4R pathways, thus potentially addressing the root cause of leptin-melanocortin pathway disorders. The company is currently developing setmelanotide for a variety of these obesity-related disorders, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome, and others.
The company has demonstrated an unwavering commitment to scientific excellence and steadfast dedication to patients throughout its history. In November 2020, the US Food and Drug Administration (FDA) approved setmelanotide, under the brand name Imcivree, for chronic weight management in patients with irritable bowel syndrome (IBS) and three rare genetic defects: POMC, PCSK1, and LEPR deficiency.
Rhythm Pharmaceuticals, guided by their mission of transforming the care of patients living with rare genetic disorders of obesity, continues to widen their reach with several ongoing clinical trials for Imcivree with the aim of further evaluating its potential benefits and safety in larger patient populations. The success of these trials is crucial for the company, as they strive to establish setmelanotide as the foundation of care for individuals living with rare genetic obesity disorders.
With a robust portfolio of product candidates and strategic collaborations in place, Rhythm Pharmaceuticals is poised to create a significant positive impact and forever change the landscape for patients suffering from rare genetic disorders of obesity. The company, listed on the NASDAQ stock exchange under the ticker symbol "RYTM," has become a beacon of hope for patients and families affected by these disorders, proving that innovative, patient-focused solutions can indeed reshape the narrative for rare disease treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Rhythm Pharmaceuticals reported strong Q3 2026 revenue of $92 million, driven by a successful U.S. launch of Imcivree for acquired hypothalamic obesity (HO) and the commencement of its launch in Japan. The company also announced the initiation of its Phase 3 bivameligon HO study, targeting a 52-week trial, and plans to start screening patients by year-end, alongside an amended bivameligon licensing agreement with LG Chem to reduce future royalty obligations. These strategic moves and financial bolstering, including a new $750 million term loan facility, are expected to support bivameligon development and global commercial execution.
LG Chem has significantly expanded its licensing agreement with Rhythm Pharmaceuticals for bivamelagon, an oral drug candidate for rare forms of obesity, increasing the total deal value to $855 million from an initial $305 million. The amended agreement, now valued at approximately 1.15 trillion won, reflects the drug's promising clinical development and includes additional upfront payments, increased milestone payments, and a revised royalty structure. Bivamelagon, an MC4R agonist, showed positive results in a Phase 2 trial and is expected to advance to global Phase 3 trials this year, offering an oral alternative to existing injectable treatments.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced strong Q3 2026 financial results, with global net product revenue from IMCIVREE reaching $92.1 million, a 29% increase from the prior quarter, driven by strong U.S. launch momentum and the commercial launch in Japan. The company also reported over 700 patient start forms for IMCIVREE in acquired hypothalamic obesity (HO) and detailed the advancement of bivamelagon into pivotal development for Prader-Willi syndrome. Additionally, Rhythm secured a five-year term loan facility for up to $750 million and amended its licensing agreement with LG Chem for bivamelagon.
Rhythm Pharmaceuticals, Inc. (RYTM) is anticipated to surpass earnings estimates for the quarter ended September 2026, driven by higher revenues. The company is expected to report a quarterly loss of $0.68 per share, a 17.1% year-over-year improvement, with revenues projected to increase by 64.7% to $84.47 million. The Zacks Earnings ESP indicates a likely positive surprise, as the Most Accurate Estimate is higher than the Zacks Consensus Estimate, combined with a Zacks Rank of #3.
Rhythm Pharmaceuticals has launched IMCIVREE in Japan for acquired hypothalamic obesity, making it available to an estimated 5,000 to 8,000 patients with National Health Insurance reimbursement. This expansion into a new reimbursed rare disease market is a key catalyst for the company, although it remains unprofitable and highly reliant on its lead therapy. Investors will now focus on the efficiency of Rhythm's local infrastructure build-out and its ability to convert regulatory approval and NHI listing into consistent treatment starts.
Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast on Tuesday, November 3, 2026, at 8:00 a.m. ET, to report its third quarter 2026 financial results and provide a corporate update. The company also announced its participation in two upcoming investor conferences in November. Additionally, the press release detailed information about Rhythm Pharmaceuticals and its lead asset, IMCIVREE® (setmelanotide), including its indications and important safety information.